Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Aminoguanine SCHEMBL21760 | 0.83 | KDM4E (0.60) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL160586 | 0.76 | ALDH1A1 (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL6686385 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL843931 | 0.76 | LMNA (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL844206 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL158423 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL42761 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL2206472 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL9115 | 0.76 | KDM4E (0.53) | KDM4EGLAALDH1A1LMNAPMP22 | |
| SCHEMBL10006403 | 0.76 | KDM4E (0.49) | KDM4EGLAALDH1A1LMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-09-25 | — | — | US | claimed |
| CN-113329739-B | Antisense oligonucleotides targeted to SCN2A for the treatment of SCN1A encephalopathy | 罗贡股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117795071-A | Antisense oligonucleotides for preventing renal dysfunction caused by endothelial dysfunction through inhibition of ephrin-B2 | 马克斯·普朗克科学促进学会 | 2024-03-29 | — | — | CN | claimed |
| WO-2023215819-A2 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-11-09 | — | — | WO | claimed |
| CN-107603976-B | Methods and compositions for RNA-directed target DNA modification and transcriptional regulation | 埃玛纽埃尔·沙尔庞捷 | 2021-10-12 | — | — | CN | claimed |
| CN-113329739-A | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathy | 罗贡股份有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-113151261-A | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-112707921-A | Synthesis of fluorescence label of enzyme inhibitor | 南京碳硅人工智能生物医药技术研究院有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-107002082-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2021-02-02 | — | — | CN | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-5650510-A | VIRICIDES OR ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-07-22 | — | — | US | claimed |
| EP-0398231-B1 | Nucleoside analogs | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1997-07-16 | — | — | EP | claimed |
| EP-0630381-B1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1997-04-09 | — | — | EP | claimed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | claimed |
| US-5386030-A | Chemical intermediates | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCE OF THE CZECH REPUBLIC (CZ) | 1995-01-31 | — | — | US | claimed |
| EP-0630381-A4 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | — | 1995-01-04 | — | — | EP | claimed |
| EP-0630381-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES. | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1994-12-28 | — | — | EP | claimed |
| US-5208221-A | Nucleotides and intermediates for herpes virus or leukemia virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-05-04 | — | — | US | claimed |
| WO-1993007157-A1 | ANTIVIRAL ACYCLIC PHOSPHONOMETHOXYALKYL SUBSTITUTED, ALKENYL AND ALKYNYL PURINE AND PYRIMIDINE DERIVATIVES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OFTHE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1993-04-15 | — | — | WO | claimed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | DHFR, DHODH, MTHFD1 | KDM4E 3659/4885GLA 1551/4885ALDH1A1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.